Clinical Use of Micronized Abiraterone for Patients with Prostate Cancer

Benjamin H. Lowentritt, MD, FACS, shares background information on micronized abiraterone and discusses its role in the evolving prostate cancer treatment landscape.

In the first article of this series, Benjamin H. Lowentritt, MD, FACS, gives an overview of micronized abiraterone and its role in the treatment of patients with metastatic castrate-resistant prostate cancer.

Benjamin H. Lowentritt, MD, FACS, provides clinical insights on the use of different formulations of abiraterone as treatment for patients with prostate cancer.

In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.

In this installment, expert Paul E. Dato, MD, discusses the value of a multidisciplinary team in managing patients with mCRPC and considers how his institution ensures patients receive best available therapy.

In the third article of this series, Paul E. Dato, MD, provides comprehensive insights on the multidisciplinary care of patients with metastatic castration-resistant prostate cancer.